Expression of fibrinolysis activators and their inhibitor in neointima of polyester vascular grafts
Source abstract
Abstract
The aim of the study was to evaluate dynamic changes in the expression of fibrinolytic system components in neointima forming in polyester vascular grafts. The study was carried out on 18 mongrel dogs divided into three groups, that underwent replacement of abdominal aorta with a polyester double velour prosthesis. Grafts were removed at 1, 4 and 12 months. The specimens were fixed according to AMeX method. Immunohistochemical labeling for von Willebrand factor (vWf), tissue plasminogen activator (t-PA), urokinase (u-PA), its receptor (u-PAR), plasminogen activator inhibitor type 1 (PAI-1) and D-dimer (DD) was performed. Increasing intensity of vWf expression on the graft luminal surface was found in successive periods of the study. A light positive t-PA and u-PA staining was shown in neointima at 1 month and its intensity was significantly increased at 4 and 12 months. Expression of u-PAR appeared at 4 months. A light positive PAI-1 and DD staining was demonstrated in neointima in all periods of the study. The results demonstrated increasing expression of fibrinolysis activators in neointima of polyester vascular grafts. Intensive expression of plasminogen activators, when compared to their inhibitor may reduce thrombotic properties of graft neointima particularly in the late period after prosthesis implantation.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Protease and Inhibitor Mechanisms · Blood Coagulation and Thrombosis Mechanisms · Infectious Aortic and Vascular Conditions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (39)
Show source-provided references
1. Enhancement of thrombus formation by vascular prostheses
2. Intraoperative outflow resistance as a predictor of late patency of femoropopliteal and infrapopliteal arterial bypasses10.1016/0741-5214(87)90093-0 ↗
3. A scanning and transmission electron microscope study of the luminal coating on Dacron prostheses in the canine thoracic aorta
4. Defective fibrinolysis10.1002/bjs.1800741018 ↗
5. The haemostatic system components of neointima forming in polyester aortic grafts in the early postoperative period
6. The biologic fate of Dacron double velour vascular prostheses–a clinicopathological study10.1007/BF02471406 ↗
7. Proof of fallout endothelialization of impervious Dacron grafts in the aorta and inferior vena cava of the dog10.1016/0741-5214(94)90279-8 ↗
8. Implant site influence on arterial prosthesis healing10.1016/S0741-5214(97)70264-7 ↗
9. Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators10.1083/jcb.94.3.631 ↗
10. Plasminogen activators and matrix metalloproteinases in angiogenesis10.1159/000468621 ↗
11. Synergism of thrombolytic agents in vivo10.1161/01.CIR.74.4.838 ↗
12. Plasminogen activator inhibitors10.1182/blood.V69.2.381.381 ↗
13. Plasminogen activator inhibitor-1 secretion by endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot10.1182/blood.V87.10.4204.bloodjournal87104204 ↗
14. Plasminogen activation by receptor bound urokinase10.1016/S0021-9258(18)98963-5 ↗
15. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia10.1182/blood.V96.8.2775 ↗
16. A new method for measuring D-dimer using immunoturbidometry10.1097/00001721-200012000-00004 ↗
17. Quantification of fibrinolytic activity in venous and prosthetic arterial grafts10.1001/archsurg.1974.01360020025006 ↗
18. Distribution and variation of thromboplastic and fibrinolytic activity of dacron aortic grafts
19. Fibrinolytic activity in pseudointima of dacron aortic grafts
20. Binding of tissue plasminogen activator to vascular grafts10.1055/s-0038-1646541 ↗
21. Antithrombotic mechanisms of urokinase immobilized polyurethane10.1055/s-0038-1647457 ↗
22. High accumulation of plasminogen and tissue plasminogen activator at the flow surface of mural fibrin in the human arterial system10.1067/mva.2000.105677 ↗
23. Expression of plasminogen activator inhibitor-1 mRNA in healthy, artherosclerotic and thrombotic human arteries and veins10.1016/0049-3848(95)90180-N ↗
24. Increased circulating plasminogen activator inhibitor-1 in patients with patent femorodistal venous bypass10.1016/0049-3848(96)00086-2 ↗
25. Plasminogen activator inhibitor-1 in neointima of vein grafts10.1161/01.CIR.96.6.1783 ↗
26. The preclotting of porous arterial prostheses10.1097/00000658-197811000-00005 ↗
27. The AMeX method. A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining
28. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques10.1177/29.4.6166661 ↗
29. Distal arterial bypass by composite grafting10.1002/bjs.1800740407 ↗
30. Clinical, biochemical, and rheologic factors affecting the outcome of infrainguinal bypass grafting10.1016/S0741-5214(96)70080-0 ↗
31. Effect of differential shear stress on platelet aggregation, surface thrombosis, and endothelialization of bilateral carotid-femoral grafts in the dog10.1016/S0741-5214(95)70005-6 ↗
32. Immunofluorescent staining for factor VIII related antigen10.1016/0022-4804(79)90124-0 ↗
33. Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis10.1097/00001721-200306000-00008 ↗
34. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery10.1161/01.RES.67.1.61 ↗
35. Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation10.1091/mbc.2.10.793 ↗
36. Intimal hyperplasia in vascular grafts10.1053/ejvs.1999.1040 ↗
37. Molecular analysis of blood vessel formation and disease
38. Rupture of pseudointima in an implanted vascular prosthesis
39. Effects and mechanism of tissue-type plasminogen activator and plasminogen activator inhibitor on vascular smooth muscle cell proliferation10.1016/S0167-5273(98)00148-X ↗